Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 3/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7900199 | 0.99 | KEAP1 (0.42) | LMNAKDM4EKEAP1ALDH1A1MC4R | |
| SCHEMBL5792763 | 0.94 | KEAP1 (0.44) | LMNAKDM4EKEAP1ALDH1A1MC4R | |
| Hydrochloric Acid SCHEMBL17871814 | 0.93 | KEAP1 (0.42) | LMNAKDM4EKEAP1ALDH1A1MC4R | |
| SCHEMBL7897470 | 0.88 | KEAP1 (0.46) | LMNAKEAP1ALDH1A1MC4RGAA | |
| SCHEMBL2339105 | 0.88 | KEAP1 (0.46) | LMNAKEAP1ALDH1A1MC4RGAA | |
| SCHEMBL5792889 | 0.88 | KEAP1 (0.46) | LMNAKEAP1ALDH1A1MC4RGAA | |
| Hydrochloric Acid SCHEMBL10638555 | 0.87 | KEAP1 (0.45) | LMNAKEAP1ALDH1A1MC4RGAA | |
| SCHEMBL7896588 | 0.87 | KCNQ2 (0.44) | KEAP1ALDH1A1MC4RGAAKCNQ2 | |
| SCHEMBL19665213 | 0.81 | KEAP1 (0.45) | KEAP1MC4RGAAKCNQ2MAPK1 | |
| Hydrochloric Acid SCHEMBL17872072 | 0.80 | KEAP1 (0.44) | KEAP1MC4RGAAKCNQ2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060079696-A1 | Substituted compounds derived from N-(benzyl)phenylacetamide, preparation and uses | GENFIT (FR) | 2006-04-13 | — | — | US | disclosed |
| WO-2006035157-A2 | SUBSTITUTED N-(BENZYL)PHENYLACETAMIDE DERIVATIVE COMPOUNDS, PREPARATION METHOD THEREOF AND USES OF SAME AS PPAR LIGANDS IN THE TREATMENT OF LIPID AND/OR GLUCIDIC DISORDERS | GENFIT (FR) | 2006-04-06 | — | — | WO | disclosed |
| US-RE37035-E1 | HYPOGLYCEMIC AGENTS | BOEHRINGER INGELHEIM KG (DE) | 2001-01-30 | — | — | US | disclosed |
| US-6143769-A | ENANTIOMORPH | KARL THOMAE GMBH (DE) | 2000-11-07 | — | — | US | disclosed |
| US-5312924-A | Compounds for lowering blood sugar and effecting metabolism | DR. KARL THOMAE GMBH (DE) | 1994-05-17 | — | — | US | disclosed |
| US-5216167-A | Hypoglycemic agents | DR. KARL THOMAE GMBH (DE) | 1993-06-01 | — | — | US | disclosed |
| EP-0147850-A2 | Phenylacetic-acid derivatives, medicines containing these compounds and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1985-07-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079696-A1 | Substituted compounds derived from N-(benzyl)phenylacetamide, preparation and uses | AADAC, NAT1, PARN | LMNA 1111/4885KDM4E 2470/4885KEAP1 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.